1939–1940: at the Sir William Dunn School of Pathology, Oxford, Ernst Chain and Howard Florey selected penicillin for a wider programme on antibacterial substances. Norman Heatley developed an assay and extraction system; Margaret Jennings, Arthur Gardner, Jean Orr-Ewing, Gordon Sanders and other colleagues contributed biological testing, bacteriology and production. The seven-author August 1940 Lancet paper reported that penicillin protected experimentally infected mice.
1941: the Oxford laboratory became a small production facility, using purpose-made ceramic vessels and extensive technical labour. The team's August 1941 report described growth, extraction, assay, animal work and early human treatment. It named the investigators' roles and acknowledged ten technicians whose work made adequate supplies possible. The favourable responses were compelling, but tiny stocks restricted treatment and made recovery of active penicillin from patients' urine worthwhile.
1941–1944: Florey and Heatley sought United States support. The US Department of Agriculture's Northern Regional Research Laboratory, wartime agencies and pharmaceutical companies improved culture media, mould strains, extraction and aerated deep-tank fermentation. By 1944, industrial production—not replication of Fleming's plate—made penicillin available in quantities useful to Allied medicine. Civilian access remained uneven and followed different national schedules.
1945 and after: the Nobel Prize recognised Fleming, Chain and Florey, a defensible but incomplete allocation of credit. Penicillin's effectiveness established the emblematic drug of the antibiotic era, while selective susceptibility and laboratory resistance were already visible in early research. The plate's later fame records this therapeutic afterlife; it did not predict all its benefits, limits or the problems created by access, prescribing and resistance.